Marisa Wexler, MS, senior science writer —

With Phase 3 clinical trial results on Ionis Pharmaceuticals’ donidalorsen for hereditary angioedema (HAE) due by mid-year, the company has struck a deal with Otsuka Pharmaceutical for the  commercialization of the preventive treatment in Europe. “We are excited to collaborate with Otsuka given their proven results in bringing…

Throughout 2023, we at Angioedema News have been bringing you coverage of the latest news related to angioedema, from basic research to clinical trials and advances in treatment. Here we’ve compiled a list of the top 10 most-read articles we’ve published this past year. We look forward to…

The monthly under-the-skin injection therapy garadacimab will be considered for approval for treating hereditary angioedema (HAE) in both the U.S. and the European Union. Developer CSL Behring announced that both the U.S. Food and Drug Administration and the European Medicines Agency have agreed to review applications of the therapy…

Prophylactic, or preventive, treatment with deucrictibant significantly reduced the rate of swelling attacks among adults with hereditary angioedema (HAE) in a Phase 2 clinical trial. “These study results, together with the compelling data from our on-demand program, further strengthens our confidence that deucrictibant can become the preferred option…

In a clinical trial, most people with hereditary angioedema (HAE) given on-demand treatment with PHVS416, an immediate-release capsule formulation of deucrictibant, saw swelling attacks begin to resolve within half an hour of taking the medication. That’s according to new data presented in a poster, titled “…

The European Commission (EC) has granted orphan drug designation to NTLA-2002, an investigational gene-editing therapy that Intellia Therapeutics is developing for hereditary angioedema (HAE). The designation is given to therapies with the potential to improve medical care for people with serious conditions that affect up to five of…

Even with long-term preventive treatment, many people with hereditary angioedema still sometimes have swelling attacks that require on-demand treatment, a review study finds.

The design of an ongoing Phase 3 clinical trial testing sebetralstat as an on-demand oral treatment for swelling attacks in hereditary angioedema (HAE) was based on feedback from patients and data from a previous Phase 2 trial. The approach was described in the study “Evaluation…

Up to one year of treatment with Takhzyro (lanadelumab) significantly reduced rates of swelling attacks and improved quality of life for children with hereditary angioedema (HAE) ages 2 through 11, according to results from the Phase 3 SPRING clinical trial. Results from the trial helped support the U.S.

New treatments for hereditary angioedema (HAE) have been life-changing for people in the U.K., but more and better efforts are needed to educate emergency workers on providing care, according to a new study. The survey study found that HAE patients in Great Britain still frequently have upsetting experiences when…